Klin Farmakol Farm. 2025;39(4):223-228 | DOI: 10.36290/far.2025.066

Pharmacotherapie of neuropathic pain

Dana Vondráčková

Subkatedra algeziologie IPVZ, Algeziologická ambulance Neurochirurgické a neuroonkologická kliniky 1. LF UK, Ústřední vojenská nemocnice a IPVZ, Praha

Neuropathic pain is one of the most severe and difficult pain to treat with significant impact on health-related quality of life. The international associations IASP and EFIC have issued recommendations for the pharmacotherapy of this pain, which are based on recommendations in most countries. The three basic lines of choice as defined by the Clinical Standard for Pharmacotherapy of Neuropathic Pain include antidepressants, gabapentinoids, anticonvulsants, and weak or strong opioids. In addition, local treatment (capsaicin, lidocaine, botox) is recommended. For individual neuropathic pain syndromes, the recommendations slightly differ. The main differences are the indications for carbamazepine, which has been indicated in the first choice only for trigeminal neuralgia. The conclusion is presented in the table according to the review and meta-analysis of neuropathic pain pharmacotherapy recently published in the Lancet.

Keywords: neuropathic pain, pharmacotherapie, neuropathic pain syndroms, guidelines.

Received: July 30, 2025; Revised: November 10, 2025; Accepted: November 10, 2025; Published: December 22, 2025  Show citation